89bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETNB research report →
About the company
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH).
- CEO
- Rohan Palekar
- IPO
- 2019
- Employees
- 93
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $2.20B
- P/E
- -6.68
- P/S
- 104798.07
- P/B
- 4.49
- EV/EBITDA
- -7.06
- Div Yield
- 0.00%
- Gross Margin
- -128.57%
- Op Margin
- -1493990.48%
- Net Margin
- -1433966.67%
- ROE
- -59.12%
- ROIC
- -55.56%
- Revenue
- $0 · 0.00%
- Net Income
- $-367,079,000 · -158.16%
- EPS
- $-3.51 · -75.50%
- Op Income
- $-384,656,000
- FCF YoY
- -184.73%
- 52W High
- $15.06
- 52W Low
- $4.16
- 50D MA
- $12.41
- 200D MA
- $9.75
- Beta
- 1.26
- Avg Volume
- 5.39M
Get TickerSpark's AI analysis on ETNB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 45,150 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 12,500 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 56,400 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 7,000 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 7,000 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 27,400 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 335,364 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 4,331,081 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 25,000 |
| Oct 30, 25 | LAPORTE KATHLEEN | sell | 45,150 |
Our ETNB coverage
Recent articles, reports, and earnings notes.
No research on ETNB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ETNB report →Similar companies
Peers in the same neighborhood.